Welcome to our dedicated page for Exicure news (Ticker: $XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exicure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exicure's position in the market.
Exicure (Nasdaq: XCUR) reported its third-quarter 2023 financial results. The company, which halted all R&D activities in September 2022 to explore strategic alternatives, had cash and equivalents of $0.9 million as of September 30, 2023, down from $8.6 million at the end of 2022, and further decreased to $0.2 million by April 30, 2024.
R&D expenses were $0 for Q3 2023, compared to $4.8 million for the same period in 2022. General and administrative expenses remained steady at $2.4 million. The net loss was $5.3 million, slightly up from $5.2 million in Q3 2022, mainly due to a loss on debt securities.
The company urgently needs additional funding to continue operations, as current cash levels are insufficient.